바이오티BTMD 주가

Biote Reaffirms FY26 Guidance For Revenue Above $190M And Adjusted EBITDA Above $38M

Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.

Biote Appoints CFO And Chief Business Officer Bob Peterson As Interim CEO And Director, Effective June 8; Bret Christensen Steps Down As CEO

Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and

[8-K] 중대 사건 — 8-K

[4] 내부자 거래

♻️ 재탕[4] 내부자 거래 — PRIMARY DOCUMENT

[SCHEDULE 13G/A] SCHEDULE 13G/A

[4] 내부자 거래 — PRIMARY DOCUMENT

♻️ 재탕[4] 내부자 거래 — PRIMARY DOCUMENT

♻️ 재탕[4] 내부자 거래 — PRIMARY DOCUMENT

♻️ 재탕[4] 내부자 거래 — PRIMARY DOCUMENT